Back

Cardiac sympathetic denervation for different cardiovascular indications - the experience of two referral centers

30 March 2025 (08:00 - 15:30)
Organised by: Logo
Congress Presentation Part of: Poster session 3: clinical management of arrhythmias Ablation of Ventricular Arrhythmias EHRA Premium Access EHRA 2025 European Heart Rhythm Association (EHRA)

About the speaker

Photo
Doctor Agnieszka Zienciuk-Krajka

Medical University of Gdansk, Gdansk (Poland)

139 More presentations in this session

Presentation thumbnail
The relationship between left atrial electroanatomical voltage mapping and CMR-based fibrosis for enhanced preplanning in atrial fibrillation ablation
Doctor Z. Dadon (Jerusalem, IL)
Abstract Slides Video
Presentation thumbnail
Practicing physicians perception of feasibility and usefulness of quality indicators of treatment for atrial fibrillation
Doctor J. Simic (Belgrade, RS)
Abstract Slides Video
Presentation thumbnail
Risk of left atrial thrombus in patients undergoing catheter ablation for atrial fibrillation and atrial flutter
Assistant Professor F. Guerra (Ancona, IT)
Abstract Slides Video
Presentation thumbnail
Clustering analysis of left atrial smax patterns: predicting atrial fibrillation termination and associations with key clinical factors
Mr J. Huh (Seoul, KR)
Abstract Slides
Presentation thumbnail
Efficacy of semaglutide in reducing atrial fibrillation recurrence post-catheter ablation: propensity score-matched analysis
Professor G. Ciconte (San Donato Milanese, IT)
Abstract

Access the full session

Session thumbnail
Poster session 3: clinical management of arrhythmias

The Event

Event poster

EHRA 2025

30 March - 1 April 2025
You may be interested in
thumbnail
Congress Presentation
Case 1 - first choice treatment: antiarrhythmic drugs or catheter ablation?
thumbnail
Congress Presentation
Case 2 - implantable cardioverter defibrillator, catheter ablation, or both for secondary prevention?
thumbnail
Congress Presentation
Ablation is alternative to ICD therapy in post-myocardial infarction patients with haemodynamically well-tolerated sustained monomorphic VT and LVEF>40%: con

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources